Zacks Research Has Optimistic Outlook of HALO Q1 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report released on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.88 per share for the quarter, up from their previous forecast of $0.87. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.30 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $6.00 EPS and FY2027 earnings at $7.39 EPS.

A number of other research firms also recently weighed in on HALO. HC Wainwright restated a “buy” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.89.

Halozyme Therapeutics Stock Down 2.3 %

HALO opened at $60.03 on Thursday. The company has a market cap of $7.42 billion, a PE ratio of 17.50, a P/E/G ratio of 0.42 and a beta of 1.32. The business has a 50 day moving average price of $60.73 and a two-hundred day moving average price of $55.32. Halozyme Therapeutics has a 52 week low of $38.88 and a 52 week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Snyder Capital Management L P increased its position in shares of Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock worth $199,294,000 after purchasing an additional 105,086 shares during the last quarter. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 8.8% in the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock worth $136,088,000 after purchasing an additional 172,971 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock worth $92,446,000 after purchasing an additional 47,795 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock worth $87,386,000 after purchasing an additional 145,617 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,697 shares of company stock worth $1,558,052 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.